Advertisement
In both Canada and Japan, continued introduction of innovative stent grafttechnologies will allow more patients with aortic disease to be treated usingendovascular techniques rather than surgery. For instance, in June 2008, W.L.Gore's TAG was the first thoracic stent graft to receive regulatory approvalin Japan. The first abdominal stent grafts were approved in 2006. Procedureswill experience robust growth over the next five years as new devices areintroduced into the Japanese and Canadian markets, extending the treatablepatient population. Successful aortic repair using stent grafts hasencouraged Japanese and Canadian physicians to adopt the procedures, expandingprocedures and revenues in both countries.
Advertisement
"Device innovation is improving the success rates of aortic stent graftswhile also expanding the treatable patient population," says Ryan Brown,Analyst at Millennium Research Group. "As these devices become increasinglyavailable in relatively underpenetrated markets, growing patient awareness ofand demand for minimally invasive aortic procedures will drive the adoption ofaortic stent grafts."
The Japanese and Canadian Markets for Peripheral Vascular Devices 2008reports provide coverage of all key industry competitors, including BostonScientific, Cook Medical, Cordis, Terumo, and W.L. Gore, among others. Globalcoverage of this report also includes US, Europe, Asia Pacific, and LatinAmerica.
About Aortic Stent Grafts
The aorta, the main artery leaving the heart, splits into two iliacarteries that transport blood to the lower extremities. An aneurysm (theweakening and bulging of a blood vessel or artery) directly above the iliacbifurcation is referred to as an abdominal aortic aneurysm (AAA); one locatedin the ascending aorta, aortic arch, or the descending thoracic aorta isreferred to as a thoracic aortic aneurysm (TAA). Stent grafts, tubes composedof fabric supported by a metal mesh, are designed to fasten tightly to theartery above and below the aneurysm. Once in place, blood passes through thestent graft rather than pushing on the bulge of the aneurysm.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc.company (www.DecisionResources.com), is the global authority on medicaltechnology market intelligence and a leading provider of strategic informationto the health care sector. Focused solely on the medical device,pharmaceutical, and biotechnology industries, the company provides its clientswith the benefits of its specialized industry expertise through publishedreports and customized consulting services.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Amy Krohn Millennium Research Group 416-364-7776 x101 [email protected]
SOURCE Millennium Research Group
